相似文献
1
Human Papillomavirus Vaccination.
N Engl J Med. 2023 May 11;388(19):1790-1798. doi: 10.1056/NEJMcp2108502.
2
HPV vaccination in Japan: what is happening in Japan?
Expert Rev Vaccines. 2019 Apr;18(4):323-325. doi: 10.1080/14760584.2019.1584040. Epub 2019 Feb 22.
3
HPV vaccination: taking the knowledge to the streets.
J R Soc Promot Health. 2008 Sep;128(5):218-9. doi: 10.1177/14664240081280051401.
4
HPV-vaccination impact in Denmark: is the vaccine working?
Expert Rev Vaccines. 2018 Sep;17(9):765-767. doi: 10.1080/14760584.2018.1509001. Epub 2018 Aug 11.
5
Linkage of individual-patient data confirm protection of prophylactic human papillomavirus vaccination against invasive cervical cancer.
J Natl Cancer Inst. 2024 Jun 7;116(6):775-778. doi: 10.1093/jnci/djae042.
6
[Grounds for the inclusion of vaccination against cervical cancer within the National Immunisation Programme].
Ned Tijdschr Geneeskd. 2008 Nov 29;152(48):2639-40; author reply 2640-1.
7
Extending vaccination periods against human papillomavirus: Lessons from the SARS-CoV-2 pandemic.
BJOG. 2024 Jun;131(7):877-879. doi: 10.1111/1471-0528.17748. Epub 2024 Jan 15.
8
From human papillomavirus to cervical cancer.
Obstet Gynecol. 2010 Jul;116(1):177-185. doi: 10.1097/AOG.0b013e3181e4629f.
9
Papillomavirus vaccine types 16 and 18: new drug. Cervical cancer: just another vaccine.
Prescrire Int. 2008 Jun;17(95):103-4.
10
Herd immunity.
Aust Fam Physician. 2007 Sep;36(9):677.
引用本文的文献
1
Call for Increased Community Education Regarding Common HPV-Associated Cancers Within the Urban Safety-Net Hospital Population.
J Cancer Educ. 2025 Sep 1. doi: 10.1007/s13187-025-02722-y.
2
Evaluation of Anti-HPV18 Antibody Titers Preceding an Incident Cervical HPV18/45 Infection.
Vaccines (Basel). 2025 Jul 2;13(7):722. doi: 10.3390/vaccines13070722.
3
Global, regional, and national estimates of burden and risk factors of female cancers in child-bearing age: A systematic analysis for Global Burden of Disease Study and Bayesian projection to 2030.
Transl Oncol. 2025 Jul 20;60:102473. doi: 10.1016/j.tranon.2025.102473.
4
Association between high-risk HPV prevalence and circumcision status among sexually experienced adult males, 2013-2016, United States.
Sex Transm Dis. 2025 Jun 23. doi: 10.1097/OLQ.0000000000002207.
5
Immunogenicity and duration of antibodies after vaccination with a two-dose series of the nine-valent human papillomavirus vaccine among Alaska Native children: a prospective cohort study.
BMC Infect Dis. 2025 Apr 30;25(1):640. doi: 10.1186/s12879-025-10961-z.
6
Epidemiological Analysis of HPV Infection in Zhangjiagang, Southern Jiangsu Province of China: A Cross-Sectional Study.
Int J Microbiol. 2025 Apr 19;2025:5576260. doi: 10.1155/ijm/5576260. eCollection 2025.
7
Advances and Challenges in the Treatment of HPV-Associated Lower Genital Tract Cancers by Immune Checkpoint Blockers: Insights from Basic and Clinical Science.
Cancers (Basel). 2025 Apr 8;17(8):1260. doi: 10.3390/cancers17081260.
8
Human papillomavirus vaccination at age 9 or 10 years to increase coverage - a narrative review of the literature, United States 2014-2024.
Hum Vaccin Immunother. 2025 Dec;21(1):2480870. doi: 10.1080/21645515.2025.2480870. Epub 2025 Apr 14.
9
HPV Infection in Children and Adolescents-A Comprehensive Review.
J Clin Med. 2025 Apr 2;14(7):2425. doi: 10.3390/jcm14072425.
10
Multi-disciplinary approaches paving the way for clinically effective peptide vaccines for cancer.
NPJ Vaccines. 2025 Apr 9;10(1):68. doi: 10.1038/s41541-025-01118-9.
本文引用的文献
1
Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination.
Vaccine. 2023 Jan 4;41(1):236-245. doi: 10.1016/j.vaccine.2022.11.044. Epub 2022 Nov 26.
2
Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial.
Lancet Glob Health. 2022 Oct;10(10):e1473-e1484. doi: 10.1016/S2214-109X(22)00309-6.
3
National Vaccination Coverage Among Adolescents Aged 13-17 Years - National Immunization Survey-Teen, United States, 2021.
MMWR Morb Mortal Wkly Rep. 2022 Sep 2;71(35):1101-1108. doi: 10.15585/mmwr.mm7135a1.
4
Immunogenicity, safety, and efficacy of the HPV vaccines among people living with HIV: A systematic review and meta-analysis.
EClinicalMedicine. 2022 Aug 3;52:101585. doi: 10.1016/j.eclinm.2022.101585. eCollection 2022 Oct.
5
HPV type-specific trends in cervical precancers in the United States, 2008 to 2016.
Int J Cancer. 2023 Jan 15;152(2):137-150. doi: 10.1002/ijc.34231. Epub 2022 Sep 26.
6
Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer.
N Engl J Med. 2022 Jun 16;386(24):2273-2282. doi: 10.1056/NEJMoa2201048.
7
Efficacy of single-dose HPV vaccination among young African women.
NEJM Evid. 2022 Jun;1(5):EVIDoa2100056. doi: 10.1056/EVIDoa2100056. Epub 2022 Apr 11.
8
Rationale and design of a double-blind randomized non-inferiority clinical trial to evaluate one or two doses of vaccine against human papillomavirus including an epidemiologic survey to estimate vaccine efficacy: The Costa Rica ESCUDDO trial.
Vaccine. 2022 Jan 3;40(1):76-88. doi: 10.1016/j.vaccine.2021.11.041. Epub 2021 Nov 29.
9
Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial.
Lancet Infect Dis. 2022 Mar;22(3):413-425. doi: 10.1016/S1473-3099(21)00327-3. Epub 2021 Nov 12.
10
The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study.
Lancet. 2021 Dec 4;398(10316):2084-2092. doi: 10.1016/S0140-6736(21)02178-4. Epub 2021 Nov 3.
Zotero 插件